476060.KQ KOE
Onconic Therapeutics
1W: +3.8%
1M: -12.7%
3M: +14.8%
YTD: -8.8%
1Y: -37.8%
₩15,710.00 ($11.69)
-210.00 (-1.32%)
Weekly Expected Move ±6.2%
₩13769
₩14739
₩15710
₩16681
₩17651
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
$11.4B
+245.3% ▲
Capital Expenditures
$303M
-114.4% ▼
4Y CAGR: +144.0%
Free Cash Flow
$11.1B
+239.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$4.0B
-68.6% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$15.1B | -$14.4B | $1.7B | -$8.1B | $15.8B |
| Depreciation & Amort. | $183M | $201M | $460M | $453M | $528M |
| Stock-Based Comp. | $163M | $472M | $578M | $1.0B | $0 |
| Change in Working Capital | -$885M | -$927M | $2.2B | -$5.7B | -$3.4B |
| Other Non-Cash Items | $6.8B | -$278M | -$774M | $4.4B | -$1.6B |
| Operating Cash Flow | -$8.9B | -$15.0B | $4.1B | -$7.8B | $11.4B |
| — Investing Activities — | |||||
| Capital Expenditures | -$3M | -$2.6B | -$1.2B | -$141M | -$303M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | -$5.9B |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | -$6M | $0 | $147M | $70M | $0 |
| Investing Cash Flow | -$9M | -$2.6B | -$1.1B | -$71M | -$6.2B |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | -$180M | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$142M | -$4M | -$40M | $0 | -$1.7B |
| Financing Cash Flow | $27.4B | $26.0B | -$40M | $19.6B | -$526M |
| Net Change in Cash | $18.5B | $8.5B | $2.8B | $12.9B | $4.0B |
| Cash End of Period | $18.9B | $27.3B | $30.1B | $43.0B | $47.0B |
| Free Cash Flow | -$8.9B | -$17.5B | $3.0B | -$8.0B | $11.1B |